USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
IPO Year:
Exchange: NYSE
Website: usana.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2023 | Buy | Sidoti | |
| 7/7/2022 | $78.00 → $53.00 | Hold → Underperform | Jefferies |
| 4/14/2022 | $86.00 | Neutral | DA Davidson |
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13D/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13D/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
11-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
ARS - USANA HEALTH SCIENCES INC (0000896264) (Filer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic
SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2023 / Helo Corp. (OTC:HLOC) ("Helo" or the "Company") is pleased to announce that Kevin Fuller has joined its executive team as president of Helo AI and chief marketing officer of Helo, effective December 1, 2023."We are delighted to welcome Kevin to our executive team," said Seán McVeigh, Helo's chief executive officer. "Kevin brings significant product development and marketing experience, arising from his previous roles as a senior executive with other leading technology and wellness companies. His passion and leadership add to the significant momentum of our Helo AI platform and upcoming products."Mr. Fuller, 53, served as cofounder and chie
USANA Health Sciences, Inc. (NYSE:USNA) today announced that consistent with the Company's planned succession strategy, Kevin Guest, USANA's Chief Executive Officer (CEO) since 2015 and Chairman of the Board since 2020, will transition to the role of Executive Chairman of the Company, effective July 1, 2023. At that time, Jim Brown, USANA's current President, will be named CEO of the Company. "It has been my great privilege to be part of USANA for over 30 years and to serve as CEO of this remarkable company for the last 8 years. I express my sincere appreciation for, and confidence in, USANA's extraordinary management team, employees and Associates for their relentless work in advancing US
USANA Health Sciences, Inc. (NYSE:USNA) today announced the appointment of Xia Ding to the company's board of directors effective October 11, 2021. Ms. Ding currently serves as Vice President of e-commerce Asia Pacific and Latin America at Nike and is well-regarded as an e-commerce and digital business leader. She has served in various management roles at several global online and omnichannel retailers, including Nike, JD.com and Hanesbrands. With the addition of Ms. Ding to the board as an independent director, the USANA board now has eight members, six of whom are independent. Kevin Guest, Chief Executive Officer and Chairman of the Board, commented, "I'm delighted to welcome Ms. Ding to
USANA Health Sciences, Inc. (NYSE:USNA), a leading developer and manufacturer of high-quality nutritional supplements, healthy foods and personal care products, today announced that Doug Hekking, Chief Financial Officer, will participate in a fireside chat and host one-on-one meetings with investors at the ICR Conference in Orlando, FL on January 13-14, 2025. The fireside chat will begin at 8:00 AM ET on January 13, 2025. A live audio webcast of the fireside chat will be available on USANA's website at https://ir.usana.com and a replay will be available on the same day. About USANA USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care
SALT LAKE CITY, Jan. 2, 2025 /PRNewswire/ -- During International Quality of Life Month, Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA), is urging individuals to focus on what truly matters—mental well-being, self-care, financial health, physical fitness, lifelong learning, and meaningful relationships. With today's rapid progress, Guest emphasizes the power of intentionality and small steps toward balance during times of unprecedented change and possibility. "Life is moving faster than ever, but the most critical investment we can make is in ourselves,"
Hiya is a fast-growing, emerging leader of high-quality children's health & wellness products. Broadens USANA's reach into the highly attractive direct-to-consumer channel driven by Hiya's powerful subscription model with runway for sustainable future growth. Expected to be immediately accretive to 2025 adjusted EBITDA. 9/30/2024 LTM net sales of $103 million, LTM net income of $19 million, and LTM adjusted EBITDA of $22 million. The Company will discuss the transaction during a conference call on Monday, December 23, 2024, at 5:00 PM ET. USANA Health Sciences, Inc. (NYSE:USNA) (the "Company," "USANA"), today announced its acquisition of a 78.8% controlling ownership stake in Hiya
Spread Kindness, Happiness Through Five Meaningful Acts of Generosity SALT LAKE CITY, Dec. 2, 2024 /PRNewswire/ -- Kevin Guest is encouraging everyone to come together to celebrate National Build Joy Day today by spreading kindness and uplifting their communities through acts of generosity—no matter how big or small. With a mission to promote compassion, connection and joy, this special day serves as a powerful reminder of the impact thoughtful actions can have on individuals and society as a whole. "National Build Joy Day is an incredible opportunity to reflect on the positiv
SALT LAKE CITY, Nov. 12, 2024 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in nutrition, was recently awarded Manufacturer of the Year for the third consecutive year by the Utah Manufacturers Association in the "mega-sized (500+ employees) companies" category. To learn more about USANA and its commitment to quality, please visit USANA.com. "Our manufacturing capabilities are one of our biggest differentiators as a company," said Jim Brown, CEO and president of USANA. "Our ability to manufacture the majority of our products in-house while maintaining extremely
SALT LAKE CITY, Nov. 1, 2024 /PRNewswire/ -- This November, a multinational leader is encouraging people everywhere to celebrate National Gratitude Month and experience the profound impact gratitude has on health and happiness. From enhancing psychological well-being to boosting physical health, gratitude has a transformative effect that can change lives in deeply meaningful ways. "I invite everyone to celebrate National Gratitude Month, a time dedicated to recognizing the lasting influence gratitude can have on our lives," said Kevin Guest, Executive Chairman at USANA Health
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 28, 2024. Key Financial & Operating Results Third quarter net sales were $200 million versus $213 million during Q3 2023. Third quarter diluted EPS was $0.56 as compared with $0.59 during Q3 2023. Company updates fiscal year 2024 net sales and diluted EPS outlook to approximately $850 million and $2.45, respectively (previously $850 million to $880 million and $2.40 to $2.55). Q3 2024 Financial Performance Consolidated Results Net Sales $200 million -6% vs. Q3 2023 No meaningful YOY FX impact -6% sequentially D
SALT LAKE CITY, Oct. 10, 2024 /PRNewswire/ -- USANA Health Sciences, Inc. is proud to announce that the Prescribers' Digital Reference® (PDR) has recently included 11 of USANA's products to their list of trusted drugs and supplements. This recognition adds further credibility to the world-renowned quality of USANA's products while placing supplemental facts directly in the hands of prescribers. Products listed in the PDR include; BiOmega, CoQuinone 30, Core Minerals, HealthPak, Hepasil DTX, MagneCal D, USANA Probiotic, Procosa, Proflavanol C100, Visionex, and Vita Antioxidant.
USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2024 results will be released after the close of market on Tuesday, October 22, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 23, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufacture
SALT LAKE CITY, Oct. 1, 2024 /PRNewswire/ -- As vibrant melodies of Country Music Month fill the air this October, there is no better time to explore the symphony between our love for music and the pursuit of mental wellness. Country music, with its rich storytelling and emotional resonance, offers more than just a soundtrack to our lives—it serves as a guiding force in achieving mental well-being, according to Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA). "Our commitment to health is underscored by the power of music to transform lives," said Guest, wh
Sidoti initiated coverage of USANA with a rating of Buy
Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously
DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00
Roth Capital reiterated coverage of USANA Health Sciences with a rating of Buy and set a new price target of $126.00 from $107.00 previously
Hiya is a fast-growing, emerging leader of high-quality children's health & wellness products. Broadens USANA's reach into the highly attractive direct-to-consumer channel driven by Hiya's powerful subscription model with runway for sustainable future growth. Expected to be immediately accretive to 2025 adjusted EBITDA. 9/30/2024 LTM net sales of $103 million, LTM net income of $19 million, and LTM adjusted EBITDA of $22 million. The Company will discuss the transaction during a conference call on Monday, December 23, 2024, at 5:00 PM ET. USANA Health Sciences, Inc. (NYSE:USNA) (the "Company," "USANA"), today announced its acquisition of a 78.8% controlling ownership stake in Hiya
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 28, 2024. Key Financial & Operating Results Third quarter net sales were $200 million versus $213 million during Q3 2023. Third quarter diluted EPS was $0.56 as compared with $0.59 during Q3 2023. Company updates fiscal year 2024 net sales and diluted EPS outlook to approximately $850 million and $2.45, respectively (previously $850 million to $880 million and $2.40 to $2.55). Q3 2024 Financial Performance Consolidated Results Net Sales $200 million -6% vs. Q3 2023 No meaningful YOY FX impact -6% sequentially D
USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2024 results will be released after the close of market on Tuesday, October 22, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 23, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufacture
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 29, 2024. Key Financial & Operating Results Second quarter net sales were $213 million versus $238 million during Q2 2023. Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023. Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00). Q2 2024 Financial Performance Consolidated Results Net Sales $213 million -11% vs. Q2 2023 -8% constant currency vs. Q2 2023
USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2024 results will be released after the close of market on Tuesday, July 23, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 24, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 30, 2024. Key Financial & Operating Results First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency. First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023. Company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00. Q1 2024 Financial Performance Consolidated Results Net Sales $228 million -8% vs. Q1 2023 -5% constant currency vs. Q1 2023
USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2024 results will be released after the close of market on Tuesday, April 30, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, May 1, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended December 30, 2023. Key Financial Results & Guidance Fourth quarter net sales were $221 million versus $228 million during Q4 2022 and $213 million during Q3 2023. Fourth quarter diluted EPS was $0.87 as compared with $0.66 during Q4 2022. Fiscal year 2023 net sales were $921 million as compared with $999 million during fiscal year 2022. Fiscal year 2023 diluted EPS totaled $3.30 versus $3.59 during fiscal year 2022. Company provides initial fiscal year 2024 net sales and diluted EPS guidance of $850 million to $920 million and $2.40 to $3.00, respect
USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter and fiscal year 2023 results will be released after the close of market on Tuesday, February 6, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, February 7, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA deve
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 30, 2023. Key Financial & Operating Results Third quarter net sales were $213 million versus $233 million during Q3 2022. Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022. Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30). Q3 2023 Financial Performance Consolidated Results Net Sales $213 million -9% vs. Q3 2022 -7% constant currency vs. Q3 2022 -$5 million YOY F